There is a significant gap in patients’ understanding of treatment options for gynecologic cancers, according to a survey ...

Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total volume in those strikes near 2,500 contracts.

GSK has shifted towards a global marketing model ... saying that publishing standards about the content is key to ensuring success. Without standards, people using the content outside of the ...

Guggenheim analyst Seamus Fernandez downgraded GSK (GSK) to Neutral from Buy without a price target following the Q3 report. While the company’s guidance appears achievable and it is a ...

GSK’s settlement, which was made without any admission of liability, will also see the company resolve a separate ‘qui tam’ ...

Drugmaker GSK shared positive results Monday from two Phase 3 trials testing its inflammatory disease drug depemokimab in people with a condition known as chronic rhinosinusitis with nasal polyps.

(Reuters) - British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...